

---

# Index

---

## A

Acidic environment, 57–59  
Acidic fibroblast growth factor (FGF-1, aFGF), 94, 98, 102–108, 119, 427  
Actinonin, 211  
Activated macrophages, 68  
Acute hypoxia, 10, 14  
Adenoviral vector, 436  
Adenyl cyclase, 145  
Adhesion molecules, 37  
Adjuvant therapy, 350  
ADP-ribose, 147, 148  
ADP-ribosylation (ADPR), 145–149  
Adrenal steroids, 242  
Adriamycin, *see* Doxorubicin  
AE-941, 175–181  
Aerobic glycolysis, 149  
AF-1, 356  
AF-2, 356  
AG-3340, 212  
Age-related macular degeneration (AMD), 130, 131, 180  
AGM-1470, *see* TNP-470  
AGM-1883 (M-IV), 394  
 $\alpha$ -linoleic acid (18:3), 245  
Alkaline phosphatase, 318  
All-*trans*-retinoic acid (ATRA), 247, 356, 358–363  
Alpha enolase, 232  
Amiloride, 166, 170  
3-Aminobenzamide, 145  
Aminosterol, 153  
Anaerobic glycolysis, 51, 60  
Anastrozole, 344  
Angiogenic index, 320  
Angiogenin, 78, 119  
Angiopoietin (Ang-1), 7, 132  
Angiostatic steroids, 153–158, 164–169, 242, 278  
Angiostatin (AP), 6, 78, 119, 193, 194, 225–234, 298, 308, 309  
Angiotropin, 78  
Annexin II, 232–234

Anti-bFGF, 387  
Antibody (LM609), 107  
Anti-CD31, 289, 327, 328, 346  
Anti-CD36 antibody, 193  
Anticoagulation, 378–381, 393  
Anti-endoglin antibody, 318  
Anti-factor VIII, 289  
Anti-gelatinase A antibodies, 216, 217  
Anti-IAP antibody, 194  
Anti-lectin antibodies, 318  
Antisense sequences, 425–427  
Antisense TSP-1 constructs, 196  
Anti-thrombin-II (AT-II), 372  
Anti-TSP-1 antibodies, 187, 188  
Antitumor alkylating agents, 278  
Anti-VEGF antibodies, 129–132, 424  
AP-1 transcription factor, 146  
Apigenin, 250  
Apoptotic index, 58, 194, 231  
Aprotinin, 216  
APTTs, 376, 378  
Arachidonic acid, 41  
Aranciamycin, 213  
Arene oxides, 412  
Aromatase inhibitor, 344  
Aryl hydrocarbon receptor nuclear translocator (ARNT) gene, 243, 244  
Ascorbic acid, 248  
Aspirin, 245  
Atherosclerotic plaques, 39, 216, 248  
ATP-dependent H<sup>+</sup> pump, 60  
Autacoids, 41  
Average tumor vascularity, 318, 319, 330  
AZT (zidovudine), 379

## B

B16 melanoma, 79, 84, 196, 304–307  
Basement membrane, 100–102, 108  
Basic fibroblast growth factor (FGF-2, bFGF), 4, 71, 78, 80–83, 93, 98–106, 108, 110, 119, 160–166, 176, 186–193, 196, 243–247, 249–252, 263, 308, 321, 327, 362, 371–380, 386–389, 410, 427–430

- Batimastat, 211–217, 399–402  
Bax oncoprotein, 325  
Bay 12-9566, 214  
BB-1101, 215  
 $\beta$ -carotene, 240, 247  
bcl-2 oncoprotein, 325, 328  
BCNU (carmustine), 168–170, 281, 284, 388  
 $\beta$ -cyclodextrin tetradecasulfate, 155, 156, 278  
BE16627B, 211  
Behcet's syndrome, 267  
bek, 98  
Bleomycin, 278  
Blood flow, 23, 51, 84  
Blood viscosity, 11  
Blood–brain barrier, 21  
Brefeldin A, 108  
Bromodeoxyuridine, 363
- C**  
CA125, 348, 403  
CA19/9, 348, 403  
Calcium uptake, 249  
Calcium-phospholipid dependent protein kinase C (PKC), 374  
Caloric stress, 242  
Cancer-specific antigens (CSAs), 401, 403, 404  
Carbogen, 31  
Carboplatin, 284, 285, 294, 328  
Carboxyamidotriazole, 249  
Carcinogenesis, 239, 242  
Carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea; BCNU), 168, 169, 283, 284, 388  
Cartilage extracts, 175, 178–180  
Cartilage, 176, 177, 181, 298  
Cathepsin B, 216  
Cathepsin G, 195  
CD102 (ICAM-2), 120, 319  
CD105 (endogolin), 319, 346, 389  
CD13 (aminopeptidase-n), 319, 390  
CD18, 120  
CD29/CD49d ( $\alpha$ 4 $\beta$ 1 integrin), 268  
CD31 (PECAM), 217, 318  
CD34 (sialomucin), 318, 319  
CD36 (glycoprotein IV), 192–194, 198, 319  
CD36 null mice, 193  
CD54 (ICAM-1), 120, 319  
CD61 (b3 integrin), 268  
CD62 E (E-selectin), 319  
Chemopreventive agents, 238, 250, 355, 359–361  
Chick embryo chorioallantoic membrane (CAM) assay, 107, 120, 154–157, 178, 187, 216, 243, 247, 265, 268, 278, 281, 361, 373, 386, 411  
Chondrocytes, 176, 248  
Chondroitin sulfate, 100, 176  
Chondromodulin-1, 177  
Chronic hypoxia, 10  
Circulating tumor markers, 348  
Cisplatin (CDDP), 169, 170, 278–282, 290–292, 328, 329, 359, 360, 388  
9-*cis*-retinoic acid (9cRA), 247, 356  
13-*cis*-retinoic acid (13cRA), 247, 359–361  
c-jun, 197  
Coagulation, 185  
Collagen gel, 120, 242  
Collagen type  $\alpha$ 1(I) gene, 107  
Collagen XVIII, 234, 309  
Collagen, 66, 100, 103, 107, 144–149, 159, 194, 195, 208, 246, 247, 268  
Collagenases, 102, 177, 205–213, 345  
Combinatorial chemistry, 209  
Comet assay, 26  
COMP (TSP-5), 191  
Complete biologic effect (CBE), 348  
Complete response (CR), 343, 393  
Continual reassessment methods, 343  
Corneal micropocket assay, 154–157, 186, 263, 266, 281, 344, 386, 410, 411, 416, 419  
Coronary balloon angioplasty, 216  
Cortisone, 154  
c-SRC, 146  
CT1746, 214  
C-X-C chemokines, 38  
Cyclic RGD peptide, 107  
Cyclin-dependent kinase cdc2, 389  
Cyclin-dependent kinase cdk2, 389  
Cyclin-dependent kinase cdk4, 389  
Cyclin-dependent kinases, 359  
Cyclophosphamide (cytoxan), 170, 267, 278–284, 287–292, 303–310, 388  
Cyclooxygenase, 245
- D**  
D5140, 215  
Daidzein, 250  
Daidzin, 250  
D- $\alpha$ -tocopherol, 248  
Deep vein thrombosis (DVT), 380  
5'-Deoxy-5-fluorouridine, 387  
Dermatan sulfate, 100

- Dexamethasone, 154  
Dextran sulfate, 105  
Diabetes mellitus, 130  
Diabetic neuropathy, 144  
Diabetic retinopathy, 106, 144, 154, 244, 265  
Diclofenac, 245  
Dietary lipid concentration, 245  
Dietary restriction, 240, 243  
1,25-Dihydroxy-vitamin D<sub>3</sub>, 247, 249, 359  
Disintegrin, 215  
Dogfish shark *Squalus acanthias*, 156  
Dormancy therapy, 231  
Dormant state, 226  
Dose-limiting toxicity (DLT), 390, 394  
Doxorubicin (adriamycin), 129, 267, 278, 287, 303, 304, 388  
Dynamic reciprocity, 4
- E**  
E-9, 318  
eck tyrosine kinase receptor, 40  
Ectoprotein kinase A, 194  
Eicosanoids, 245  
Elastase, 195  
Elastin, 205, 206  
Elongin ABC complex, 123  
EM-12, 265–268  
EM-138, 265, 266  
Embryogenesis, 119  
Embryonic development, 154  
Emphysema, 216  
EMT-6 mammary carcinoma, 286, 290, 309  
Endogenous angiogenesis inhibitors, 67  
Endoglin, 319, 346, 389  
Endometriosis, 131  
Endostatin, 78, 119, 131, 175, 225, 234, 309  
Endothelial cell-stimulating factor (ESAF), 176  
Endothelins, 243  
Epicortisol (11  $\alpha$ -hydrocortisone), 155  
Epidemiologic methodology, 238  
Epidermal growth factor (EGF), 78, 374  
Eppendorf KIMOC-6650 histograph, 27, 28  
Equol, 250  
Erythropoietin (Epo), 122  
E-selectin (CD62 E), 268, 319, 322, 389  
Estrogen receptor (ER), 344, 347, 423  
Ethylene vinyl acetate (EVAc) sustained-release polymer, 157  
Eukaryotic initiation factor 2-associated protein (eIF2), 390  
Extracellular acidification rate, 167  
Extracellular acidity, 52  
Extracellular matrix (ECM), 65–72, 100–110, 121, 155, 163, 205, 216, 233, 252, 321, 415, 416  
Extracellular pH (pHe), 53, 54, 55, 57, 60
- F**  
Factor VIII (Von Willebrand factor), 242, 318, 327–331, 347, 372  
Factor XII, 373  
Febufen, 213  
FGF binding protein (FGF-BP), 108, 110, 424, 428, 436  
FGF receptor-1 (FGFR-1), 97–99, 106  
FGF-3, 96, 98  
FGF-4, 96, 98, 103, 104, 374  
FGF-5, 96, 98  
FGF-6, 96, 98  
FGF-7 (keratinocyte growth factor), 97, 98  
FGF-8 (androgen-induced growth factor), 97, 98  
FGF-9 (glia-activating factor), 97, 98  
FGFR-2, 99, 106  
FGFR-3, 98  
Fibonacci schema, 343  
Fibrin, 39, 78, 195  
Fibrinolysis, 185  
Fibroblast collagenase, 211–214  
Fibroblast growth factor (FGF), 4, 78, 93, 101  
Fibroblasts, 7, 10  
Fibrocartilage, 176  
Fibronectin, 66, 100, 107, 163, 205, 206  
Fisetin, 250  
Flavone acetic acid, 267  
Flavonoids, 250  
flg tyrosine kinase, 97  
Flk-1 (fetal liver kinase-1), 124–127, 130, 131  
Flt-1 (fms-like tyrosine kinase), 124–129, 131  
5-Fluorouracil (5-FU), 170, 303, 304, 388  
Focal adhesion kinase (FAK), 193  
Fractalkine, 39  
Fumagillin, 175, 281, 385, 390  
Futoenone derivatives, 213  
Fyn null mice, 193
- G**  
Galardin, 211, 216  
Gastric ulcers, 216  
Gelastatins, 213  
Gelatinase-A (MMP-2), 98, 205, 206, 212–214, 217, 307, 308, 399, 401

- Gelatinase-B (MMP-9), 205, 206, 212–217, 307, 399  
 Gelatinases, 345  
 Gelsolin, 234  
 Gene therapy, 426  
 Genistein, 167, 250, 252, 286–288  
 Genistin, 250  
 Glucose transporter GLUT1, 124, 243  
 Glycitein, 250  
 Glycitin, 250  
 Glycosaminoglycan (GAG), 109  
 Glycosyl phosphatidylinositol, 109  
 Glypican, 100, 101  
 Graft-versus-host disease (GVHD), 267, 408, 409, 417, 418  
 Granulocyte-macrophage-stimulating factor (GM-CSF), 40  
 Graves' disease, 131  
 Green's function model, 12  
 Gro $\alpha$ , 39
- H**
- Halofuginone, 107, 108  
 Hammerhead ribozymes, 424, 425, 431, 437  
 Haseloff-Gerlach ribozyme, 424, 427  
 Helix-loop-helix protein, 123  
 Hemangioma, 70, 81–83, 104  
 Heparan sulfate proteoglycans, 66, 100, 427  
 Heparin, 100–103, 122, 154–158, 164, 216, 242, 278, 372, 380  
 Heparinase, 80  
 Heparin-binding growth factors (HBGFs), 93, 108, 376–380  
 Heparin-binding sites, 191, 192  
 Hepatocyte growth factor (HGF), 41, 119, 160, 327, 347  
 HIV-1 Tat protein, 129  
 hst-1, 96  
 hst-2, 97  
 Hyaline, 176  
 Hydrocortisone, 156, 242, 278  
 Hydrogenated fats, 245  
 Hydron pellets, 186, 187  
 Hydroxamic acid, 210–213  
 Hyaluronic acid (HA), 107  
 Hyperthermia, 388  
 Hypoxia reoxygenation injury, 16  
 Hypoxia, 3, 4, 7–17, 23–32, 51, 59, 60, 109, 122–126, 130, 144–148, 243, 244, 294, 417  
 Hypoxia-inducible factor 1 (HIF-1), 122–126, 146, 243, 244
- I**
- IAP, 189, 192–195  
 ICAM-1, 120  
 ICI 182780, 347  
 IFN regulatory factor-1 (IRF-1), 359  
 IFNAR-1, 358  
 IFN- $\gamma$  receptor (IFNGR), 358  
 IFN-stimulated gene factor-3 (ISGF-3), 358  
 IFN-stimulated response elements (ISREs), 358  
 Indomethacin, 245  
 Infiltrating leukocytes, 37  
 Inflammatory bowel disease, 216  
 Insulin-like growth factor II (IGF-II), 59, 144  
 Insulin-like growth factor-1 (IGF-1), 123, 144, 389  
 Integrin  $\alpha\beta$ 3, 107, 268, 298  
 Integrin  $\alpha\beta$ 5, 132, 268  
 Integrin receptors, 268, 434  
 Interferon- $\alpha$  (IFN- $\alpha$ ), 81–85, 104, 170, 247, 298, 358–363, 388  
 Interferon- $\alpha$  receptor-2 (IFNAR-2), 358  
 Interferon- $\beta$  (IFN- $\beta$ ), 78–85, 170, 307, 308, 358–363, 388  
 Interferon- $\gamma$  (IFN- $\gamma$ ), 38, 84, 194, 298, 307, 308, 358, 363, 388  
 Interferons (IFNs), 358, 361, 363  
 Interleukin-1 (IL-1), 71, 82, 123, 144  
 Interleukin-12 (IL-12), 298, 300–308  
 Interleukin-2 (IL-2), 361  
 Interleukin-6 (IL-6), 43, 123  
 Interleukin-8 (IL-8), 38, 39, 69–72, 78–82, 85, 119, 189, 347  
 Interleukin-8 receptor, 43  
 Interstitial collagenase (MMP-1), 120, 205, 206, 216, 399, 401  
 Interstitial environment, 51  
 Interstitial pressure, 27  
 Intracellular acidity, 52  
 Intracellular pH (pHi), 54–58, 60  
 Intraocular neovascularization, 130, 131  
 Intratumor pH, 60  
 Intratumoral vessels, 289, 309  
 IP-10, 39  
 Isoflavone, 287  
 Isoflavones, 250  
 Isoflavonoids, 250
- J**
- JAK1, 358  
 JAK-2 tyrosine kinase, 40  
 Janus kinase (JAK), 358

**K**

- Kallikrein, 373
- Kaposi's sarcoma (KS), 43, 44, 68, 95, 96, 99, 104, 129, 267, 346, 374, 379, 390, 413, 419
- KDR receptor, 122, 124–129, 131, 321
- Keratan sulfate, 100
- Keratinocyte growth factor (KGF), 123
- Ki67, 347
- Krogh cylinder model, 12

**L**

- Lactate dehydrogenase, 167
- Lactate, 144–149
- Lactate/proton symporter, 57
- Lactic acid, 51
- Laminin, 66, 100, 107, 163, 205, 206, 298
- Laser Doppler flowmetry, 14
- Legumes, 250
- Lepromatous leprosy, 267, 408, 409, 417, 418
- Leukotrienes, 246
- Lewis lung carcinoma (LLC), 226, 278–282, 288–291, 294, 298, 309, 310, 388, 417
- Lewis lung carcinoma-low metastatic (LLC-LM), 226, 229, 231, 233
- Linoleic acid (18:2), 245
- Lipid peroxidation, 248
- Lipoxygenase, 245
- LM609, 298
- Low energy transfer (LET) ionizing radiation, 23
- Lung metastases, 281, 285, 288–302, 304, 433–435
- Lupus erythematosus, 267, 408, 418
- Luteolin, 250
- L- $\omega$ -nitro-L-arginine methyl ester (L-NAME), 246, 247
- Lysophosphatidic acid, 189

**M**

- Macronex, 267
- Macrophage inflammatory protein-1, 43
- Macrophages, 6, 37, 67, 69–72, 85, 103, 104, 109, 144–149, 186, 195, 232, 308, 321
- Macular degeneration, 119, 154, 265, 268
- Magnetic resonance spectroscopy (MRS), 26, 54
- Marimastat, 348, 399–404
- Marine fish oils, 246
- Mast cells, 6

- Matrigel, 159, 216, 308, 374
- Matrilysin (MMP-7), 206, 211, 212, 215, 216, 345, 399
- Matrix metalloproteinase inhibitors (MMPI), 210, 214–217, 399, 401
- Matrix metalloproteinase-2 (MMP-2), 78, 98, 179
- Matrix metalloproteinase-9 (MMP-9), 78
- Matrix metalloproteinases (MMPs), 7, 40, 66, 188, 205, 322, 345, 346
- Matystatin, 211
- Maximum tolerated dose (MTD), 342–344, 390, 391, 394, 400
- Medroxyprogesterone acetate (MPA), 154, 156
- Melanoma, 29, 53, 81–83, 95
- Melphalan, 278, 281
- Membrane-type (MT)-MMP (MMP-14), 206, 207, 399
- Meta-analysis, 324, 403
- Metalloelastase (MMP-12), 206, 231, 232, 345
- Metastasis, 77, 78, 80–84, 105
- Methioninamiopeptidase-2 (MetAP-2), 319, 390
- 2-Methoxyestradiol, 158, 166, 169, 242
- Microenvironment, 81
- Microvasculature, 23
- Microvessel density (MVD), 169, 242, 317–331, 346, 347, 423, 434
- Minerals, 237
- Minocycline, 170, 213, 278, 283, 285–287, 290, 294, 309, 388
- Mitomycin C, 388
- Model-guided dosing, 343
- Monocyte chemotactic protein-1 (MCP-1), 38, 39
- Mononuclear phagocytes, 67
- Multidrug resistance (MDR), 346
- Multiple sclerosis (MS), 215
- Musculoskeletal syndrome, 404

**N**

- Na<sup>+</sup>/H<sup>+</sup> antiporter, 56–58
- Na<sup>+</sup>/H<sup>+</sup> ATPase, 60
- Na<sup>+</sup>/H<sup>+</sup> exchangers (NHEs), 5, 40, 166, 167, 170
- Nerve regeneration, 185
- Neurite outgrowth, 185
- Neutrophil collagenase (MMP-8), 205, 206, 211, 212
- NHE-1, 166, 170
- NHE-2, 166
- NHE-3, 166, 167

- Nicotinamide, 78, 145  
Nitric oxide (NO), 3, 16, 42, 121, 125, 246  
NO synthase (NOS), 125, 246, 247  
NO synthase inhibitors, 42, 125, 247  
*N*-phthalidoglutamide, 403  
Nuclear retinoid receptors, 247, 356  
Nutritional status, 237–239  
*N*ω-mono-methyl-L-arginine (L-NMMA), 246, 247
- O**
- O*-desmethyllangolensin, 250  
Oligoadenylate synthase (OAS), 359  
Omega-3 fatty acids, 245, 246  
Oncogenic adapter protein NcK, 250  
Oncogenic ras, 123  
Optimal biologic dose (OBD), 344, 401  
Ordideoxyinosine, 379  
Ornithine decarboxylase, 84  
Overall response rate (ORR), 343, 344, 348  
Overall survival (OS), 323, 346  
Oxygen consumption, 11–14, 24, 25  
Oxygen enhancement ratio, 23, 32  
Oxygen tension (pO<sub>2</sub>), 11, 27–31, 122  
Oxygen, 144, 145, 148, 294, 417  
Oxyhemoglobin saturation (HbO<sub>2</sub>), 26
- P**
- p53, 15, 19, 123, 197, 244, 325–328  
p55, 40  
p75 TNF receptor, 40  
Paclitaxel, 284–286, 292, 294  
Panendothelial markers, 323, 330  
Partial biologic effect (PBE), 348  
Partial oxygen pressure (pO<sub>2</sub>), 23, 27  
Partial response (PR), 343  
PCNA labeling rate, 328  
Pentosan polysulfate (PPS), 105, 371–381  
Pentoxifylline, 267  
Perflubron emulsion, 294  
Perfusion rate, 24  
Perlecan, 100, 102  
pH, 23, 52  
Pharmacokinetics, 402, 410  
Phase I clinical trials, 342, 343, 376–379, 390–394, 401–404, 414  
Phase II clinical trial (RPTD), 342, 343, 349, 376, 390, 394, 401, 404  
Phase III clinical trials, 349, 404  
Phosphatidylinositol 3-kinase, 125, 250  
Phospholipase A2, 41  
Phospholipase C, 109  
Phospholipase C-β, 246  
Phospholipase C-γ (PLC-γ), 125  
Phthalimide, 407  
2-Phthalimidino-glutaric acid, 414, 415  
Phytochemicals, 249  
Placenta growth factor, 119, 125, 128  
Plasmin, 109, 121, 195, 226, 232  
Plasminogen activator (PA), 67, 102, 122, 156, 175, 226–234  
Plasminogen activator inhibitor-1 (PAI-1), 120, 154, 166, 242, 252, 322  
Plasminogen, 122, 175, 226–234  
Platelet factor IV, 38, 78, 298  
Platelet-activating factor (PAF), 40, 41  
Platelet-derived endothelial cell growth factor (PD-ECGF), 78, 82, 84  
Platelet-derived growth factor (PDGF), 4, 78, 122, 124, 160, 374, 389  
Pleiotrophin (PTN), 327, 424, 426, 429–435, 437  
Polysulfonated compounds, 157  
pp60src, 374  
Procollagen, 191  
Progesterin, 154  
Prognostic value, 331  
Prolactin, 119, 242, 243  
Proliferative index, 231  
Properdin, 191  
Prostaglandin E-1 (PGE-1), 41, 189  
Prostaglandins, 245, 246  
Protamine, 105, 157, 298  
Protein kinase C (PKC), 248, 250  
Proteoglycans, 176  
Proteolytic-resistant fibrillar collagens, 205  
Prothombin, 393  
Provisional fibrin matrix, 4  
PSA, 348, 403, 414  
P-selectin (CD62 P), 319, 322  
Psoriasis, 71, 119, 131, 180, 181  
PTEN/MCMAC, 197  
PTN mRNA, 431–433, 435  
PTN-targeted ribozymes, 429–432, 435, 436  
Pthalimide, 265  
Pthaloyl glutamic acid (PG acid), 265, 266  
Pycnidione, 213
- Q**
- Quality of life (Q-TWIST), 349, 395
- R**
- RA response elements (RARES), 357  
Radiation therapy, 32, 59, 109, 278, 281, 299–309, 328, 350, 359, 360, 388

- Radiosensitization, 23, 27  
RAR/RXR heterodimer, 356  
ras GTPase activating protein (GAP), 125, 250  
ras p21, 197, 374  
Recombinant murine interleukin-12 (rmIL-12), 298–308  
Reduced-energy intake, 242, 244  
Relapse-free survival (RFS), 323, 346  
Remodeling stroma, 103  
Renal cell cancer (HRCC), 80, 84  
Reoxygenation, 10, 15  
Restriction of total food intake, 240  
Retinal vessels, 127  
Retinoblastoma protein (Rb), 389  
Retinoic acid receptors (RARs), 356–361  
Retinoid receptor knockout mice, 356  
Retinoid X receptors (RXRs), 356, 357  
Retinoid-IFN synergy, 359  
Retinoids, 68, 71, 247, 248, 355, 362, 363  
RG-13577, 106  
Rheumatoid arthritis (RA), 119, 131, 215, 267, 408, 414, 418  
ribozymes, 423–430, 436, 437  
Rip1 Tag2 transgenic mice (bTC), 108  
Ro 32-3555, 215
- S**
- Saporin, 106  
SC44463, 211, 213  
Scatter factor (SF), 68, 69, 160, 187, 189, 193, 327  
Secreted protein acidic and rich in cysteine (SPARC), 66, 107  
Secreted protein B.61, 40  
Seed and soil hypothesis, 79  
Selenium, 240  
Serine proteases, 188  
Serine proteinase inhibitor (serpin)  $\alpha$ -1, 205, 206  
Shark cartilage, 175–179, 181  
Sodium pentosan polysulfate (PPS), 105, 371–381  
Sodium-proton ( $\text{Na}^+/\text{H}^+$ ) exchangers (NHEs), 5, 40, 166–170  
Somatoline, 298  
Somatostatin, 298  
Soy, 240, 250, 252, 286  
Spermidine, 157  
Spheroid tumor model, 146  
Squalamine, 153, 156–169  
SRC family, 126, 197  
*src*-family kinase Fyn, 193  
*src*-related kinases, 193, 197
- Stable disease (SD), 343, 393  
STAT1, 358  
STAT2, 358  
Stein-Leventhal syndrome, 131  
Stochastic approximation methods, 343  
Stomelysin-3 (MMP-11), 205–207  
Stromelysin-1 (MMP-3), 205, 206, 211–216, 345, 399  
Structure–activity-relationship (SAR), 208, 209, 211, 212  
Substance P, 42  
14(sulfated)- $\beta$ -cyclodextrin, 388  
Sulindac, 267  
Superoxide anion, 15  
Supidimide, 267  
Suramin, 95, 105, 155, 157, 287–289  
Surrogate end-points/ markers, 325, 395, 401–404  
Syndecan, 100  
Systems approach, 277
- T**
- Tamoxifen, 344, 387  
Tat gene, 104  
Taxanes, 284  
Tecogalen (DS4152), 105  
Temozolamide (TMZ), 388  
Teratogenicity, 265, 267, 268  
Tetracyclines, 213  
Tetrafluorothalamide, 266  
Tetrahydrocortisol (THC), 155, 156, 242, 278, 388  
Thalidomide, 263–268, 407–419  
Thiotepa, 388  
Thrombin, 39, 109  
Thrombocytopenia, 381  
Thrombomodulin, 247  
Thromboplastin, 393  
Thrombospondin-1 (TSP-1), 70–72, 78–80, 107, 119, 154, 185–197  
Thymidine phosphorylase (TP), 321, 327  
Tie family of receptors, 7, 132  
Tie-2 receptor, 7, 132  
Tirapazamine, 417  
Tissue inhibitors of metalloproteinases (TIMPs), 66, 154, 176, 177, 207, 213–217, 298, 346  
Tissue remodeling, 4  
Tissue repair, 4, 143  
Tissue-type plasminogen activator (tPA), 120, 226, 232, 233, 247, 373  
TNP-470 (AGM1470), 168, 170, 175, 263–265, 281–294, 309, 385–394

- TNP-470-minocycline, 282–287, 290, 292, 294  
Toxicity-based escalation schemes, 343  
Transcription activation function (AF-1), 356  
Transferrin, 176  
Transforming growth factor- $\alpha$  (TGF- $\alpha$ ), 10, 71, 78, 119  
Transforming growth factor- $\beta$  (TGF- $\beta$ ), 6, 10, 42, 67, 82, 119, 122–126, 176, 177, 186–189, 195, 389  
Transient hypoxia, 14  
Triacylglycerols (triglycerides), 245  
TSP-1 null mice, 187, 197  
TSP-2, 189, 190  
Tumor dormancy, 395  
Tumor microenvironment, 83, 237, 248  
Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), 39, 119, 126, 186, 215, 267, 268, 308  
Tumor oxygen pressure (pO<sub>2</sub>), 10, 11, 14–16, 24–26, 28–32, 59, 60, 122  
Tumor perfusion, 12, 14  
Tumor-associated macrophages (TAM), 68, 71  
Tyk2, 358  
Type I collagen, 66, 107, 216  
Type II collagen, 176  
Type IV collagen, 163, 205, 318  
Type IV collagenases (gelatinases), 66, 80, 85, 205, 206, 307, 308, 323  
Type VIII collagen, 107  
Type XVIII collagen, 175  
Type-1 collagenase, 177  
Tyrosine kinase receptor cck-2, 98
- U**  
Urokinase-type plasminogen activator (uPA), 40, 120, 205, 206, 226, 232, 247, 252, 389
- V**  
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), 4, 69, 78–84, 100–105, 110, 119–126, 131, 144–148, 160, 163, 185, 189, 243, 246–252, 263–268, 321–326, 347, 410, 424  
Vascular hot spots, 318, 346  
Vascular hyperpermeability, 4  
Vascular index, 319  
Vascular smooth muscle cells (VSMC), 362, 363, 373  
VCAM-1, 120, 268  
VEGF gene, 121  
VEGF<sub>110</sub>, 233  
VEGF<sub>121</sub>, 121  
VEGF<sub>165</sub>, 121, 132  
VEGF<sub>181</sub>, 121  
VEGF<sub>206</sub>, 121  
VEGF-B, 119  
VEGF-C, 119, 124  
VEGF-D, 119  
VEGF-related peptide (VRP), 124  
Vimentin, 318  
Vinblastine, 361  
Vitamin A, 240, 247, 355, 361  
Vitamin C (ascorbic acid), 248  
Vitamin D, 249, 359  
Vitamin E, 248  
Vitamins, 237  
Vitelline, 128, 178  
Vitronectin, 163  
VLA-4, 120  
V-myc, 197  
Von Hippel-Lindau (VHL) tumor-suppressor gene, 123, 128
- W**  
Wound healing, 4, 69, 93, 103, 110, 119, 126, 128, 143, 144, 148, 154, 268, 385, 387, 427
- Y**  
YM-24074, 211
- Z**  
Zidovudine, 379